TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,030, Maintains Buy Rating
TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,030, Maintains Buy Rating
TD Cowen將再生元製藥公司的目標股價從1030美元調升至1200美元，並維持買入評級。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間